



Contact: [REDACTED]  
tel.: +32-2-642.53.39  
fax: +32-2-642.52.10  
Secretariat: NCL.Biologicals@sciensano.be  
E-mail: genevieve.waeterloos@sciensano.be

BE/22/0141

**TO WHOM IT MAY CONCERN****CERTIFICATE FOR THE RELEASE OF COMIRNATY VACCINE**

The following lot [REDACTED] of **COMIRNATY** vaccine, Pandemic COVID-19 vaccine (mRNA), produced by [REDACTED], whose number appears on the labels of the final containers, meets all national requirements and complies with the relevant specifications in the European registration file<sup>1,2</sup>.

This product is manufactured and controlled in accordance with the requirements for *Good Manufacturing Practices for Pharmaceutical Products: Main Principles*<sup>3</sup>, *Good Manufacturing Practices for Biological Products*<sup>4</sup> and *Guidelines for Independent Lot Release of Vaccines by Regulatory Authorities*<sup>5</sup>.

This certificate is based on examination of the summary protocol of manufacturing and control, and independent laboratory testing.

**Final Lot Nr****Nr of released  
containers  
in this final lot****Expiry date**

[REDACTED]

[REDACTED]

May 2022

Type of packaging: Vial

Number of doses per unit pack: 6 doses

The Chief of the National Control Laboratory

Digitally signed by [REDACTED]

Date: 2022.01.20 11:14:04 +01'00'

<sup>1</sup> If any national requirements have not been met, specify which one(s) and indicate why the release of the lot(s) has nevertheless been authorized by the NCL.

<sup>2</sup> With the exception of provisions on distribution and transport, which the NRA or NCL may not be in a position to assess.

<sup>3</sup> WHO Technical Report Series, Nr. 986, 2014, Annex 2

<sup>4</sup> WHO Technical Report Series, Nr. 999, 2016, Annex 2

<sup>5</sup> WHO Technical Report Series, Nr. 978, 2013, Annex 2